ACCREDITATION STATEMENT
32nd Clinical Applications for Age Management Medicine
In support of improving patient care, this activity has been planned and implemented by The Foundation for Care Management (FCM) and Age Management Medicine Group (AMMG). FCM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This program is approved for 25 AMA Category 1 Credits TM
Healthcare provider should only claim credit commensurate with the extent of their participation in this activity
COURSE DESCRIPTION
This conference provides evidence-based research on new methods and topics in the Management of to educate healthcare practitioners and provide treatment tools that improve patient outcomes.
COURSE OBJECTIVES
Upon completion of this workshop, the healthcare professional will be able to:
- Describe new scientific evidence-based studies for the use of DNA based genetic testing and how to clinically apply this knowledge to individualized patient treatment plans to improve patient outcomes.
- Present evidence-based research on core issues considered essential for clinicians who practice age management/preventive medicine and how to clinically apply this knowledge to individualized patient treatment plans.
- Using evidence based research review the diagnosis and treatment of Traumatic Brain Injury. Summarize the available scientific literature discussing the primary traumas and secondary effect of inflammation in patients with TBI
- Present evidence-based research on clinical interventions for Brain Health.
- Present new and emerging scientific markers of aging.
- Describe the genomics of the pandemic and Treatment protocols which are evidence based methods to prevent or treat COVID.
- Discuss and present a literature review for the use of hormones in men and women, particularly the controversial use of estrogen in men, testosterone replacement and use of progesterone.
- Discuss new scientific research on the use of Plasma Dilution Therapy, Psychedelics and the use of Naltrexone Therapy in medicine.
DISCLOSURES STATEMENTS
Planning Committee:
Florence Comite, MD has no relevant financial relationships with ineligible companies to disclose
Mary Corry, MSN has no relevant financial relationships with ineligible companies to disclose
Elliot Dinetz, MD has no relevant financial relationships with ineligible companies to disclose
Gregory Fillmore has no relevant financial relationships with ineligible companies to disclose
Mark Gordon, MD is a Speaker for University Compounding
Rob Kominarek, DO has no relevant financial relationships with ineligible companies to disclose
Cesar Pellerano, MD has no relevant financial relationships with ineligible companies to disclose
John Rush, MD has no relevant financial relationships with ineligible companies to disclose
George Shapiro, MD is the Medical Director for Organicell
Disclosures for all Faculty:
Mickey Barber, MD has no relevant financial relationships with ineligible companies to disclose
Dale Bredesen, MD is a consultant for Life Seasons and Apollo Health
John Carrozzella, MD has no relevant financial relationships with ineligible companies to disclose
William Clearfield, DO has no relevant financial relationships with ineligible companies to disclose
Florence Comite, MD has no relevant financial relationships with ineligible companies to disclose
Mary Corry, MSN has no relevant financial relationships with ineligible companies to disclose
Angela DeRosa, DO is the Medical Director for Belmar Pharma Solutions
Derrick DeSilva, Jr., MD has no relevant financial relationships with ineligible companies to disclose
Elliott Dinetz, MD has no relevant financial relationships with ineligible companies to disclose
Brian Gerber, MD has no relevant financial relationships with ineligible companies to disclose
Mark Gordon, MD is a speaker for University Compounding Pharmacy
Sharon Hausman-Cohen, MD is the Chief Medical Officer for IntellexxDNA
Dallas Kingsbury, MD is the Medical Director for Organicell and Cellularity
Lauren Klein, PA-C has no relevant financial relationships with ineligible companies to disclose
Robert Kominiarek, DO has no relevant financial relationships with ineligible companies to disclose
John W. Leardi, Esq has no relevant financial relationships with ineligible companies to disclose
Edwin N. Lee, MD has no relevant financial relationships with ineligible companies to disclose
John E. Lewis, PhD is a speaker for Daiwa Health Development and Ownership interest in Morris Formulations, LLC (Dr. Lewis Nutrition)
Melissa Loseke Ablett, DO has no relevant financial relationships with ineligible companies to disclose
Ashley L. Madsen, PA-C has no relevant financial relationships with ineligible companies to disclose
Luis Martinez, MD has no relevant financial relationships with ineligible companies to disclose
Paul Psychogios, MD has no relevant financial relationships with ineligible companies to disclose
Neal Rouzier, MD is a speaker for Evexias
George Shapiro, MD is the Medical Director for Organicell
Kenneth Sharlin, MD has no relevant financial relationships with ineligible companies to disclose
David C. Socol, MD has an ownership interest is Advanced Huemeomics, LLC
David Stickler, MD has no relevant financial relationships with ineligible companies to disclose
Ian White, MS, Ph.D. has an ownership interest in Neobiosis, LLC and advisor for Onogen, Lilium, and Regenerative Health Management, LLC
Program Reviewers
Mary Corry, MSN and Dana Burnett, M. Ed have no relevant financial relationships to disclose.
All relevant financial relationships for faculty, planning committee and program reviewers have been reviewed and mitigated.
Conflict of Interest Disclosure Policy
Identify, Mitigate, and Disclose Relevant Financial Relationships
Many healthcare professionals have financial relationships with ineligible companies. These relationships must not be allowed to influence accredited continuing education. The Foundation for Care Management (FCM) as the accredited provider is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships are defined as relevant if the educational content is related to the business lines or products of the ineligible company. As an accredited provider FCM collects information from planners, faculty and other in control of educational content and conducts an extensive review process. Financial relationships are identified, reviewed and mitigated. In some cases, speakers and committee members may be excluded. All relevant financial relationships are disclosed to learners in this handout as required by the ACCME.